BioCentury
ARTICLE | Clinical News

Halozyme gains on Phase I pancreatic cancer data

May 17, 2013 1:32 AM UTC

Halozyme Therapeutics Inc. (NASDAQ:HALO) gained $1.24 (18%) to $7.98 on Thursday after reporting data from 24 evaluable patients in the open-label, dose-escalation Phase Ib portion of a Phase I/II tri...